(Q37846370)

English

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.

scientific article published on March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

Europe PubMed Central

Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

atrial fibrillation

0 references

1 reference

based on heuristic

inferred from title

Nikolaos Kakouros

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Irene Savelieva

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Antonios Kourliouros

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

A John Camm

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

1 March 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

308-328

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21345926%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Increasing prevalence of atrial fibrillation and flutter in the United States

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

A multicenter risk index for atrial fibrillation after cardiac surgery

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation?

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and atrial fibrillation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Role of connexins in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Rhythm control versus rate control for atrial fibrillation and heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM trial.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Atrial fibrillation and heart failure: natural history and pharmacological treatment

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Irbesartan in patients with heart failure and preserved ejection fraction

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Left ventricular hypertrophy and clinical outcomes in hypertensive patients

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Single-chamber versus dual-chamber pacing for high-grade atrioventricular block.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation?

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Current concepts in the pathogenesis of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Histological substrate of atrial biopsies in patients with lone atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Inflammation as a risk factor for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Dose-related effect of statins on atrial fibrillation after cardiac surgery

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Dose dependent effect of statins on postoperative atrial fibrillation after cardiac surgery among patients treated with beta blockers.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effects of preoperative statin treatment on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Association of statin therapy and the risk of atrial fibrillation in patients with a permanent pacemaker.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Statins and polyunsaturated fatty acids for treatment of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+currents and Na+current in human atrial myocytes

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Polyunsaturated fatty acid modulation of voltage-gated ion channels

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+/Ca2+ exchange currents in HEK293t cells

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

n-3 (omega-3) polyunsaturated fatty acids prevent acute atrial electrophysiological remodeling

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Fish intake and risk of incident atrial fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative).

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmo

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery?

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

The effect of dexamethasone on side effects after coronary revascularization procedures.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

The effects of steroids on the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting surgery: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Risk of atrial fibrillation with high-dose corticosteroids

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Respiratory medications and the risk of cardiac arrhythmias

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat.

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEUROPACE%2FEUR002

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37846370&oldid=2104983614"